Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160732 · ClinicalTrials.gov registry record · Phase 1
Allogenic Islet Cell Transplantation
A Phase 1 study of Diabetes Mellitus, Type 1, sponsored by University of Chicago.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00160732 is a Phase 1 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 50 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00160732, a Phase 1 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by University of Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes. In addition, initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatment. The "Edmonton Protocol" of using specific anti-rejection drugs without steroids is also being evaluated.
Conditions Studied
Interventions
- PROCEDURE Intraportal infusion of islet cells
- DRUG Allogenic islet cells (human, U. Chicago)
Study Locations (1)
Illinois
- The University of Chicago Hospitals - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-10 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160732
The ClinicalTrials.gov registry entry for NCT00160732 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Intraportal infusion of islet cells is the first listed.
NCT00160732 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00160732 about?
NCT00160732 is a clinical study titled "Allogenic Islet Cell Transplantation". The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle and/or complex patients with type 1 diabetes. In addition, initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatmen...
What is the current status of trial NCT00160732?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2003-10. Estimated completion is 2030-10.
What conditions does trial NCT00160732 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT00160732?
The interventions under investigation include: Intraportal infusion of islet cells (PROCEDURE), Allogenic islet cells (human, U. Chicago) (DRUG).
Who is sponsoring clinical trial NCT00160732?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00160732 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
RECRUITING · Phase 1
-
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
RECRUITING · Phase 1
-
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
RECRUITING · Phase 1
-
Islet Transplantation for Patients With Type 1 Diabetes
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.